| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.39 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $65.09 $60.55 (7%) | 🛒 Add to cart |
| 120 | $0.64 | $86.78 $76.69 (12%) | 🛒 Add to cart |
| 180 | $0.61 | $130.17 $109.99 (16%) | 🛒 Add to cart |
| 270 | $0.59 | $195.26 $160.45 (18%) | 🛒 Add to cart |
| 360 | $0.59
Best per pill | $260.35 $210.90 (19%) | 🛒 Add to cart |
Synonyms
| |||
Similar products
More info:
tamoxifen
Tamoxifen citrate represents one of those fascinating compounds that bridges multiple therapeutic domains - originally developed as a fertility treatment in the 1960s before its anti-estrogen properties were fully appreciated. The journey from failed contraceptive to cornerstone breast cancer therapy illustrates how sometimes the most valuable discoveries emerge from unexpected places. What we’re dealing with here is a selective estrogen receptor modulator (SERM) with tissue-specific effects that continue to surprise clinicians even after decades of use.
arimidex
Anastrozole, marketed under the brand name Arimidex, represents a cornerstone in the endocrine therapy arsenal for hormone receptor-positive breast cancer. This nonsteroidal aromatase inhibitor fundamentally alters the hormonal landscape in postmenopausal women by blocking the conversion of androgens to estrogens in peripheral tissues. Unlike earlier generations of hormonal therapies that carried more significant side effect profiles, Arimidex offers a targeted approach with a generally favorable tolerability profile, though it’s certainly not without its own set of challenges that we’ve had to navigate clinically.
aromasin
Aromasin, known generically as exemestane, is an oral steroidal aromatase inactivator classified as a hormonal therapy medication rather than a dietary supplement. It’s structurally an androstenedione analogue that irreversibly binds to the aromatase enzyme, permanently disabling its function in converting androgens to estrogens throughout the body. This mechanism makes it particularly valuable in estrogen receptor-positive breast cancer management, where reducing circulating estrogen levels can significantly impact disease progression. Aromasin: Potent Estrogen Control for Hormone-Sensitive Cancers - Evidence-Based Review 1.
avodart
Dutasteride, marketed as Avodart, represents one of the more interesting developments in urological pharmacotherapy over the past two decades. As a 5α-reductase inhibitor, it occupies a unique therapeutic niche that’s often misunderstood by both patients and younger clinicians who didn’t practice during its initial clinical trials. The molecule’s dual inhibition capability gives it distinct advantages in certain clinical scenarios, though we’ve learned through experience that its applications extend beyond what the original labeling suggested.
bupropion
Bupropion is an atypical antidepressant belonging to the norepinephrine-dopamine reuptake inhibitor (NDRI) class, distinct from the more common SSRIs. Initially approved for depression in 1985, it’s become a cornerstone treatment for major depressive disorder and smoking cessation, with off-label uses expanding to ADHD and sexual dysfunction caused by other antidepressants. Its unique mechanism avoids serotonin pathways, which explains its different side effect profile - no sexual dysfunction or weight gain typically, but higher seizure risk at higher doses.
Clomid: Evidence-Based Ovulation Induction and Fertility Treatment - Comprehensive Review
Clomiphene citrate, commonly known by its brand name Clomid, is an oral selective estrogen receptor modulator (SERM) that has been a cornerstone in reproductive medicine for decades. Initially developed in the 1960s, this medication works by blocking estrogen receptors in the hypothalamus, which tricks the body into perceiving low estrogen levels. This deception prompts increased production of gonadotropin-releasing hormone (GnRH), subsequently stimulating the pituitary gland to release more follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
estriol
Estriol, specifically 17β-estriol, represents the mildest of the three primary endogenous estrogens produced in the human body, alongside estrone and estradiol. Unlike its more potent counterparts, estriol exhibits unique binding affinity and activity at estrogen receptors, resulting in a distinct clinical profile that has garnered significant interest for various therapeutic applications. Historically recognized for its dramatic rise during pregnancy, where it serves as a major placental estrogen, estriol’s therapeutic potential extends far beyond obstetrics into menopausal symptom management, urogenital health, and even neuroinflammatory conditions.
evista
Raloxifene hydrochloride, marketed as Evista, represents one of the more nuanced tools in our endocrine arsenal. When I first started prescribing it back in the late 90s, we were all still figuring out exactly where this selective estrogen receptor modulator (SERM) fit in our treatment algorithms. The initial excitement about having something that could potentially give us the bone benefits of estrogen without the breast and uterine risks was tempered by real-world questions about who would actually benefit long-term.
Femara: Potent Estrogen Suppression for Hormone-Sensitive Breast Cancer - Evidence-Based Review
Letrozole, marketed under the brand name Femara among others, is an oral non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the aromatase enzyme, thereby reducing estrogen production in the body. This medication is a cornerstone in oncology for its efficacy in both adjuvant and metastatic settings. 1. Introduction: What is Femara? Its Role in Modern Medicine Femara represents a significant advancement in endocrine therapy for breast cancer management.